title: Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis.
abstract: Current treatments for rheumatoid arthritis (RA) have long-term side effects such that new treatments are needed that can safely help manage the disease. There is a growing appreciation that GABA receptors (GABA-Rs) on immune cells provide new targets that can be used to modulate immune cell activity. Here, we show for the first time that activation of peripheral GABA-Rs can inhibit the development of disease in the collagen-induced arthritis (CIA) mouse model of RA. Mice that received oral GABA had a reduced incidence of CIA, and those mice that did develop CIA had milder symptoms. T cells from GABA-treated mice displayed reduced proliferative responses to collagen and their APC had a reduced ability to promote the proliferation of collagen-reactive T cells. Thus, GABA downregulated both T-cell autoimmunity and APC activity. Collagen-reactive T cells from GABA-treated mice displayed reduced recall responses in the presence of GABA ex vivo, indicating that GABA consumption did not desensitize these cells to GABA. GABA-treated mice had reduced collagen-reactive IgG2a, but not IgG1 antibodies, consistent with reduced Th1 help. The levels of serum anti-collagen IgG2a antibodies were correlated significantly with the CIA disease scores of individual mice. Our results suggest that activation of peripheral GABA-Rs may provide a new modality to modulate T cell, B cell, and APC activity and help ameliorate RA and other inflammatory diseases.
authors: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095-1735, USA.
authors: Jide
authors: J
authors: Tian
authors: Jing
authors: J
authors: Yong
authors: Hoa
authors: H
authors: Dang
authors: Daniel L
authors: DL
authors: Kaufman
references: Arzneimittelforschung. 1981;31(9):1511-23
references: 7030354
references: Biomed Pharmacother. 1998;52(5):214-9
references: 9755818
references: Springer Semin Immunopathol. 2006 Jun;27(4):443-56
references: 16738955
references: Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2580-5
references: 20133656
references: J Neurochem. 1990 Feb;54(2):363-72
references: 2405103
references: Life Sci. 1997;61(19):1861-78
references: 9364191
references: J Neuroimmunol. 2007 Aug;188(1-2):64-8
references: 17599468
references: Epilepsy Res. 1987 May;1(3):209-12
references: 3143549
references: Nature. 2003 May 15;423(6937):356-61
references: 12748655
references: J Exp Med. 1983 Aug 1;158(2):378-92
references: 6886622
references: Arthritis Rheum. 1997 Jan;40(1):5-18
references: 9008595
references: Annu Rev Pathol. 2009;4:417-34
references: 18954286
references: Immunol Rev. 1990 Dec;118:193-232
references: 2079326
references: Nat Rev Immunol. 2006 May;6(5):394-403
references: 16622478
references: N Engl J Med. 2004 Jun 17;350(25):2591-602
references: 15201416
references: Am J Med. 2007 Nov;120(11):936-9
references: 17976416
references: J Exp Med. 1996 Apr 1;183(4):1561-7
references: 8666914
references: N Engl J Med. 1990 May 3;322(18):1277-89
references: 2271017
references: J Immunol. 2004 Oct 15;173(8):5298-304
references: 15470076
references: J Neuroimmunol. 1999 Apr 1;96(1):21-8
references: 10227421
references: Nat Med. 1996 Dec;2(12):1348-53
references: 8946834
references: Mol Immunol. 2006 Mar;43(9):1432-42
references: 16213022